15.2 Acute Decompensated Heart Failure & Cardiogenic Shock

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

15.2 Acute Decompensated Heart Failure & Cardiogenic Shock

Key Takeaways Explain This Topic AI

Stevenson hemodynamic classification stratifies acute decompensated heart failure into four distinct quadrants based on perfusion (Warm vs Cold) and congestion (Wet vs Dry); Warm and Wet (Profile B) accounts for ~80% of presentations and is treated with aggressive IV loop diuretics and IV vasodilators, while Cold and Wet (Profile C) signifies cardiogenic shock requiring urgent inotropic/vasopressor and mechanical circulatory support.

Diagnostic workup of dyspnea in suspected heart failure requires careful biomarker interpretation: BNP <100 pg/mL or NT-proBNP <300 pg/mL has >95% negative predictive value to exclude acute heart failure; NT-proBNP cutoffs for ruling IN acute HF are age-stratified: >450 pg/mL (<50 years), >900 pg/mL (50–75 years), and >1,800 pg/mL (>75 years); BNP levels are falsely elevated by renal dysfunction and female sex, and falsely depressed by obesity (BMI ≥30 kg/m²).

First-line pharmacotherapy for Warm and Wet acute heart failure is intravenous loop diuretics (initial IV dose should equal 1.0 to 2.5 times the patient's total daily home oral furosemide dose, or 20–40 mg IV furosemide in loop-naive patients); sublingual or IV nitroglycerin should be added early for rapid venodilation and preload/afterload reduction, especially in hypertensive acute pulmonary edema.

Non-Invasive Positive Pressure Ventilation (NIPPV: CPAP or BiPAP) is indicated for acute pulmonary edema with respiratory distress (tachypnea >25 breaths/min, SpO2 <90%), rapidly improving hemodynamics by decreasing LV afterload and preload, reducing intubation rates by ~60%, and significantly lowering in-hospital mortality.

In cardiogenic shock (SBP <90 mmHg, cardiac index <2.2 L/min/m², PCWP >15 mmHg, serum lactate >2.0 mmol/L), norepinephrine is the first-line vasopressor to restore coronary and systemic perfusion pressure; dobutamine (beta-1 inotrope) is added for inotropic support once BP is stabilized, whereas chronic beta-blockers must be maintained during mild-to-moderate decompensation but strictly withheld or discontinued in cardiogenic shock.

Last updated: September 2026

Stevenson Hemodynamic Classification & Clinical Phenotyping

Acute decompensated heart failure (ADHF) is a heterogeneous clinical syndrome characterized by the sudden or gradual worsening of heart failure signs and symptoms requiring emergent medical intervention. Bedside hemodynamic phenotyping is guided by the Stevenson Classification , which stratifies patients into four distinct quadrants based on the assessment of congestion ("Wet" vs "Dry") and perfusion ("Warm" vs "Cold") . STEVENSON HEMODYNAMIC 2x2 MATRIX

• CONGESTION (PCWP >18 mmHg)
• Orthopnea, JVD, S3, Crackles, Edema

• DRY (Absent) WET (Present)
• ┌──────────────────────┬──────────────────────┐
• WARM (Normal) │ PROFILE A │ PROFILE B │
• Adequate │ "Warm & Dry" │ "Warm & Wet" │
• Perfusion │ • Compensated HF │ • ~80% of ADHF │
• CI >2.2 │ • Outpatient medical │ • Congested, perfused│
• │ optimization │ • IV Loop Diuretics │
• │ │ + IV Vasodilators │
• PERFUSION ├──────────────────────┼──────────────────────┤
• │ PROFILE L │ PROFILE C │
• COLD (Low) │ "Cold & Dry" │ "Cold & Wet" │
• Hypoperfusion │ • Dehydration / │ • CARDIOGENIC SHOCK │
• CI <2.2 │ Overdiuresis │ • Mortality 30-50% │
• Lactate >2 │ • Cautious fluid │ • Vasopressors & │
• │ challenge (250 mL) │ Inotropes (Norepi, │
• │ │ Dobutamine, MCS) │
• └──────────────────────┴──────────────────────┘
• Clinical Markers of Congestion ("Wet")

Reflects elevated left ventricular filling pressures (Pulmonary Capillary Wedge Pressure [PCWP] >18 mm Hg) and central venous congestion (Central Venous Pressure [CVP] >10 mm Hg):

Left-Sided Congestion : Orthopnea (quantified by number of pillows required), paroxysmal nocturnal dyspnea (PND), tachypnea, bilateral inspiratory bibasilar crackles (rales), and an S3 gallop (pathognomonic for rapid deceleration of blood into a noncompliant, dilated ventricle).

Right-Sided Congestion : Jugular Venous Distention ( JVD >8 cm H2O at 45°), positive hepatojugular reflux, hepatomegaly, ascites, and bilateral dependent peripheral pitting edema.

Clinical Markers of Hypoperfusion ("Cold")

Reflects a depressed cardiac index (<2.2 L/min/m²) and systemic hypoperfusion:

Physical Exam : Cold, clammy extremities, pale or mottled knees, narrow pulse pressure (proportional pulse pressure [SBP - DBP] / SBP <25%), and delayed capillary refill.

End-Organ Dysfunction : Acute altered sensorium (cerebral hypoperfusion), oliguria (<0.5 mL/kg/h), prerenal azotemia (disproportionate rise in Blood Urea Nitrogen with BUN/Creatinine ratio >20:1), and lactic acidosis (arterial/venous lactate >2.0 mmol/L).

• Diagnostic Evaluation & Biomarker Interpretation
• B-Type Natriuretic Peptides (BNP & NT-proBNP)

B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are cleaved from proBNP in equal amounts and secreted by ventricular cardiomyocytes in direct response to increased myocardial wall stretch and diastolic transmural wall tension.

• Exclusion (Rule-Out) Cutoffs (High Sensitivity / NPV >95%)
• BNP <100 pg/mL

NT-proBNP <300 pg/mL Levels below these thresholds make acute decompensated heart failure highly improbable and mandate an investigation for non-cardiac causes of dyspnea (COPD exacerbation, asthma, pulmonary embolism, pneumonia).

Age-Stratified "Rule-In" Diagnostic Cutoffs (ICON Study)

Because renal clearance declines and vascular stiffness increases with age, NT-proBNP requires age-stratified cutoffs to optimize specificity:

• Age <50 years : NT-proBNP >450 pg/mL
• Age 50 to 75 years : NT-proBNP >900 pg/mL
• Age >75 years : NT-proBNP >1,800 pg/mL
• Critical Confounders and Clinical Caveats

OBESITY CAVEAT (The Low BNP Paradox) : In patients who are overweight or obese (BMI ≥30 kg/m²), circulating BNP and NT-proBNP levels are paradoxically depressed by up to 50% . This occurs due to increased expression of natriuretic peptide clearance receptors (NPR-C) on adipocytes, blunted release from pericardial fat, and altered neurohormonal clearance. Clinicians must lower diagnostic rule-in thresholds by 50% (e.g., BNP cutoff ≥50 pg/mL) in obese individuals to avoid missing severe pulmonary congestion.

RENAL DYSFUNCTION : NT-proBNP is cleared 100% via passive renal excretion, whereas BNP is cleared by both renal excretion and enzymatic degradation via neprilysin. In chronic kidney disease (serum creatinine >2.0 mg/dL or eGFR <60 mL/min), NT-proBNP accumulates markedly; an adjusted rule-in cutoff of NT-proBNP >1,200 pg/mL is recommended.

THE ARNI / SACUBITRIL PEARL : Sacubitril (the neprilysin inhibitor component of Sacubitril/Valsartan [Entresto]) blocks the neutral endopeptidase neprilysin, which degrades BNP. Consequently, treatment with sacubitril leads to an artifactual increase in serum BNP levels that does not reflect clinical worsening. In contrast, NT-proBNP is NOT a substrate for neprilysin ; NT-proBNP levels decrease in parallel with clinical improvement and must be used exclusively to assess heart failure status in patients taking an ARNI.

Point-of-Care Ultrasound (POCUS)

POCUS provides immediate, non-invasive assessment of cardiopulmonary hemodynamics:

Lung Ultrasound (LUS) : Identifies B-lines ("lung rockets") —vertical, hyperechoic, laser-like reverberation artifacts arising from the pleural line that extend to the bottom of the screen without fading and move with lung sliding. The presence of ≥3 B-lines per intercostal space in ≥2 bilateral zones demonstrates a sensitivity of 94% and specificity of 92% for cardiogenic pulmonary edema, significantly outperforming traditional chest radiography.

Inferior Vena Cava (IVC) Ultrasound : A plethoric, dilated IVC (>2.1 cm) with <50% inspiratory collapse during a spontaneous sniff indicates elevated right atrial pressure (>15 mm Hg) and systemic venous volume overload.

Chest Radiography (CXR)

Radiographic findings correlate sequentially with pulmonary capillary wedge pressure:

Cephalization of Pulmonary Vessels (PCWP 13–18 mm Hg) : Upper lobe pulmonary veins dilate to equal or exceed lower lobe vessels due to redistribution of blood flow.

Interstitial Pulmonary Edema (PCWP 18–25 mm Hg) : Characterized by Kerley B lines (thin, horizontal, 1–2 cm linear densities at the lateral lung bases perpendicular to the pleura, representing fluid accumulation in interlobular septa), peribronchial cuffing, and loss of distinct vascular margins.

Alveolar Pulmonary Edema (PCWP >25 mm Hg) : Bilateral, fluffy, confluent perihilar alveolar opacities classically described as a "bat-wing" or "butterfly" pattern , sparing the peripheral lung cortex.

Associated Features : Cardiomegaly (cardiothoracic ratio >0.5 on PA film) and blunting of costophrenic angles indicative of transudative pleural effusions (bilateral or right-sided > left-sided).

Acute Management of Warm & Wet Heart Failure (Profile B)

Profile B ("Warm and Wet") accounts for approximately 80% of hospital presentations for ADHF. Therapy focuses on rapid decongestion through preload reduction and diuresis without compromising systemic renal perfusion.

Step 1: Intravenous Loop Diuretic Therapy

Loop diuretics (furosemide, bumetanide, torsemide) act on the Na+-K+-2Cl- cotransporter in the thick ascending limb of the Henle loop, inducing rapid natriuresis and diuresis.

Dosing Strategy (The DOSE Trial Protocol) :

Loop-Naive Patients : Initiate intravenous furosemide 20 to 40 mg IV bolus (or bumetanide 1 mg IV, or torsemide 20 mg IV).

Chronic Oral Loop Diuretic Therapy : Administer an initial IV bolus dose that is 1.0 to 2.5 times the patient's total daily home oral dose in IV milligrams . For example, a patient prescribed furosemide 40 mg orally daily should receive 40 to 80 mg IV furosemide as the initial bolus. (Remember that oral furosemide has an average bioavailability of ~50%; therefore, 40 mg IV furosemide represents twice their home oral bioavailable dose).

Bolus vs Continuous Infusion : The landmark DOSE trial established that intermittent bolus dosing every 12 hours and continuous infusion achieve identical clinical efficacy; however, high-dose strategies (2.5x home dose) produce more rapid dyspnea relief and fluid loss without increasing 60-day adverse outcomes.

Diuretic Response Assessment & Titration :

Check a spot urine sodium at 2 hours post-diuretic (target >50 to 70 mEq/L) or monitor hourly urine output (target >100 to 150 mL/h over the first 6 hours).

If the diuretic response is inadequate, double the IV loop diuretic dose up to maximum single doses (e.g., furosemide 160–200 mg IV).

Sequential Nephron Blockade : In patients with refractory diuretic resistance (often caused by compensatory hypertrophy of distal convoluted tubule cells), add an oral thiazide diuretic—such as metolazone 2.5 to 5 mg PO administered 30 minutes prior to the loop diuretic, or IV chlorothiazide 500 mg —to achieve synergistic dual-nephron sodium blockade.

Step 2: Intravenous Vasodilator Therapy

Vasodilators rapidly unload the failing left ventricle, reducing myocardial wall stress and acute dyspnea. They are particularly indicated in patients with hypertensive acute pulmonary edema (SBP >140 mm Hg) or "flash" pulmonary edema.

Sublingual Nitroglycerin : Administer 0.4 mg sublingually every 5 minutes while obtaining IV access.

Intravenous Nitroglycerin : Initiate at 10 to 20 mcg/min, titrating rapidly by 10 to 20 mcg/min every 5 minutes up to 100 to 200 mcg/min. At low-to-moderate doses (<100 mcg/min), nitroglycerin produces selective venodilation , reducing preload and left ventricular end-diastolic pressure. At higher doses (>100 mcg/min), it induces modest arteriolar dilation, reducing afterload.

Intravenous Sodium Nitroprusside : Potent, balanced arterial and venous vasodilator. Initiate at 0.3 mcg/kg/min, titrating up to 2.0 mcg/kg/min. Indicated for acute severe hypertensive crises, severe acute aortic regurgitation, or acute mitral regurgitation. Requires continuous intra-arterial blood pressure monitoring. Carries a risk of cyanide and thiocyanate toxicity with prolonged infusions (>48 hours), high doses, or renal impairment.

Step 3: Non-Invasive Positive Pressure Ventilation (NIPPV)

In patients with acute cardiogenic pulmonary edema who present with respiratory distress (tachypnea >25 breaths/min, SpO2 <90%, accessory muscle use), NIPPV should be applied immediately:

Modality : Continuous Positive Airway Pressure ( CPAP 5 to 10 cm H2O ) or Bilevel Positive Airway Pressure ( BiPAP: IPAP 10–15 cm H2O, EPAP 4–6 cm H2O ).

Physiologic Mechanisms :

Preload Reduction : Positive intrathoracic pressure decreases systemic venous return to the right heart.

Afterload Reduction : Positive intrathoracic pressure decreases left ventricular transmural pressure gradient, lowering LV afterload and systolic myocardial workload.

Alveolar Recruitment : Opens fluid-filled, atelectatic alveoli, improving functional residual capacity, clearing alveolar fluid back into the interstitial space, and reversing ventilation-perfusion mismatch.

Clinical Outcomes : Multiple randomized controlled trials have demonstrated that NIPPV reduces the endotracheal intubation rate by ~60% and produces a statistically significant reduction in in-hospital mortality compared to oxygen therapy alone.

Step 4: Beta-Blocker Management Rules in Acute Decompensation

The handling of chronic beta-blockers in acute decompensation is a high-yield board topic:

Rule 1: CONTINUE Chronic Beta-Blockers During Mild-to-Moderate Decompensation : If the patient was previously stable on an evidence-based beta-blocker (carvedilol, metoprolol succinate, bisoprolol) and presents with congestion without cardiogenic shock or profound bradycardia, continue their chronic beta-blocker therapy (maintaining full dose or temporarily reducing by 50%). Abrupt discontinuation triggers an acute rebound catecholamine surge, worsens tachycardia, and is associated with increased in-hospital and 60-day mortality.

Rule 2: DISCONTINUE Chronic Beta-Blockers in Cardiogenic Shock : If the patient exhibits signs of cardiogenic shock (Profile C: hypotension, cool extremities, lactic acidosis, requirement for inotropes), beta-blockers must be held or immediately discontinued due to their negative inotropic effects.

Rule 3: NEVER Initiate or Up-Titrate Beta-Blockers in Acute Decompensation : Beta-blockers must NEVER be started or increased in dose in a congested, acutely decompensated patient. Beta-blockers should be initiated only when the patient has achieved complete euvolemia (Profile A), has been successfully weaned from IV diuretics and vasodilators, and is clinically stable prior to hospital discharge.

Cardiogenic Shock: Hemodynamics, Vasoactive Support & Mechanical Devices

Cardiogenic shock (Stevenson Profile C: "Cold and Wet") is a state of critical end-organ hypoperfusion caused by primary cardiac pump failure. It carries an in-hospital mortality rate of 30% to 50%.

Clinical and Hemodynamic Diagnostic Criteria

Persistent Hypotension : Systolic BP <90 mm Hg or mean arterial pressure (MAP) drop >30 mm Hg from baseline for >30 minutes.

Depressed Cardiac Index : CI <2.2 L/min/m² (and typically <1.8 L/min/m² without support).

Elevated Filling Pressures : Pulmonary Capillary Wedge Pressure (PCWP) >15 mm Hg (typically >18 to 20 mm Hg).

Overt Hypoperfusion : Oliguria (<0.5 mL/kg/h), cool and clammy skin, mottled knees, altered mental status, and arterial serum lactate >2.0 mmol/L .

Vasoactive Support: Vasopressors & Inotropes VASOPRESSOR & INOTROPIC ESCALATION

• ┌────────────────────────────────────────────────────────────────────────────────────────┐
• │ FIRST-LINE VASOPRESSOR: NOREPINEPHRINE (0.02 to 1.0 mcg/kg/min) │
• │ • Potent Alpha-1 vasoconstrictor + modest Beta-1 inotrope │
• │ • SOAP II Trial: Superior to dopamine (lower mortality, 50% fewer arrhythmias) │
• │ • Restores coronary and systemic perfusion pressure (Goal: MAP ≥65 mm Hg) │
• └───────────────────────────────────────────┬────────────────────────────────────────────┘
• │
• ▼ (Once MAP ≥65 mm Hg stabilized)
• ┌────────────────────────────────────────────────────────────────────────────────────────┐
• │ INOTROPIC SUPPORT: AUGMENT FORWARD CARDIAC OUTPUT & STROKE VOLUME │
• ├───────────────────────────────────────────┬────────────────────────────────────────────┤
• │ DOBUTAMINE (2.5 to 20 mcg/kg/min) │ MILRINONE (0.125 to 0.75 mcg/kg/min) │
• │ • Synthetic Beta-1 > Beta-2 agonist │ • Phosphodiesterase-3 (PDE-3) Inhibitor │
• │ • Increases cAMP, contractility & SV │ • Prevents cAMP degradation (Inodilator) │
• │ • Causes mild peripheral vasodilation │ • Decreases afterload & pulmonary vascular │
• │ • Adverse: Tachyarrhythmias, angina │ resistance; unloads RV and LV │
• │ • Ineffective if heavy beta-blockade │ • Ideal for patients on chronic beta-block │
• │ │ • Renal clearance; long t1/2; hypotension │
• └───────────────────────────────────────────┴────────────────────────────────────────────┘

Vasopressor of Choice: Norepinephrine :

In the landmark SOAP II trial (Sepsis Occurrence in Acutely Ill Patients), norepinephrine was proven to be significantly superior to dopamine in patients with cardiogenic shock. Dopamine was associated with a statistically significant increase in mortality and a twofold increase in serious tachyarrhythmias. Dopamine is no longer recommended as first-line therapy.

Norepinephrine provides potent alpha-1-mediated vasoconstriction that restores systemic vascular resistance and coronary perfusion pressure, accompanied by modest beta-1-adrenergic inotropic support.

Inotropic Support: Dobutamine vs Milrinone :

Dobutamine : First-line inotrope when blood pressure is borderline. Acts directly on beta-1 receptors to increase contractility and stroke volume. May trigger sinus tachycardia and ventricular ectopy.

Milrinone : Second-line or preferred agent in patients chronically treated with beta-blockers (milrinone acts downstream of the beta-receptor by inhibiting PDE-3). Because it induces potent pulmonary and systemic vasodilation ("inodilator"), it can cause severe hypotension; avoid loading boluses in acute shock. Milrinone is cleared 100% by the kidneys and requires dose reduction in renal failure.

Mechanical Circulatory Support (MCS)

When pharmacological therapy fails to restore tissue perfusion, temporary mechanical circulatory support must be deployed rapidly:

Intra-Aortic Balloon Pump (IABP) : Positioned in the descending aorta distal to the left subclavian artery. Inflates during diastole (augmenting coronary artery perfusion) and deflates immediately prior to systole (vacuum effect reducing LV afterload and stroke work). Provides modest cardiac output augmentation (~0.5 L/min). Contraindicated in severe aortic insufficiency or aortic dissection.

Microaxial Left Ventricular Assist Device (Impella) : Catheter-mounted axial flow Archimedes screw pump inserted retrogradely across the aortic valve into the left ventricle. Continuously pulls blood directly from the LV cavity and expels it into the ascending aorta, delivering 2.5 to 5.0 L/min of non-pulsatile forward flow . Directly unloads the left ventricle, reduces PCWP, and markedly decreases myocardial oxygen consumption.

Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) : Drains desaturated venous blood from the right atrium or femoral vein, pumps it through an external membrane oxygenator, and returns pressurized, oxygenated blood into the femoral artery or ascending aorta. Provides complete biventricular and respiratory circulatory support, but increases left ventricular afterload (frequently paired with an Impella [ECPELLA] to decompress the left ventricle).

Loading diagram... Hemodynamic Stratification and Stepwise Escalation in Heart Failure & Shock